<DOC>
	<DOCNO>NCT00412802</DOCNO>
	<brief_summary>The objective VALIDE study validate 25 % dose reduction enoxaparine patient moderate renal failure ( creatinine clearance 30 50 ml/min ) hospitalize acute coronary syndrome provide steady state similar anti Xa level plasma compare obtained patient without renal failure receive usual dose 1 mg/kg subcutaneously every 12 hour . 140 per - protocol patient plan include .</brief_summary>
	<brief_title>Adaptation Dose Enoxaparin Moderate Renal Failure Patients With Acute Coronary Syndrome</brief_title>
	<detailed_description>Included patient hospitalize acute coronary syndrome indication enoxaparin treatment . A initial dose 1 mg/kg administrate patient . According creatinine clearance , next dos ( every 12 hour subcutaneously ) adjust 25 % dose reduction creatinine clearance comprise 30 50 ml/min . After fourth dose , anti-Xa plasma level ( main endpoint ) measure peak ( 3 5 hour dose administration ) . Residual value antiXa also measure fifth dose administration ( secondary criterion ) . The objective demonstrate bio-equivalence efficacy anti-Xa value obtain patient moderate rela failure compare patient creatinine clearance high 50 ml/min . Thrombotic bleeding event record hospitalisation . 140 per-protocol evaluable consecutive patient obtain : 70 creatinine clearance high 50 ml/min 70 patient creatinin clearance 30 50 ml/min .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Patients hospitalize acute coronary syndrome Indication enoxaparin treatment Informed consent Myocardial infarction ST elevation Inclusion later 12 hour first enoxaparin dose administration Creatinine clearance low 30 ml/min History thrombopenia induce heparin Platelet count low 100.000 / mm3 Age &lt; 18 Pregnancy History hemorrhagic stroke Contraindication enoxaparin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>enoxaparine</keyword>
	<keyword>acute coronary syndrome</keyword>
	<keyword>renal failure</keyword>
	<keyword>dose adaptation</keyword>
</DOC>